FDA Busy Sorting OTC Monograph Ingredients Anticipating System Overhaul
Executive Summary
FDA has yet to finalize about one-third of its OTC monographs and several hundred ingredients do not have a final GRASE determination. Sorting will help the agency determine which of the 800 active OTC monograph ingredients are designated as needing more information to establish GRASE under a faster system based on administrative orders.
You may also be interested in...
OTC Homeopathic Market Could Shrink Under US FDA Risk-Based Oversight, Trade Groups Say
US FDA’s draft guidance for homeopathic products could result in consumer confusion, force sales of the products largely online and create a three-year backlog in review of products that have a safe track record, industry trade tells the agency. Agency plans to replace the existing compliance policy guide that largely delegated oversight to the Homeopathic Pharmacopeia of the US with risk-based enforcement by FDA.
OTC Homeopathic Market Could Shrink Under US FDA Risk-Based Oversight, Trade Groups Say
US FDA’s draft guidance for homeopathic products could result in consumer confusion, force sales of the products largely online and create a three-year backlog in review of products that have a safe track record, industry trade tells the agency. Agency plans to replace the existing compliance policy guide that largely delegated oversight to the Homeopathic Pharmacopeia of the US with risk-based enforcement by FDA.
Petition Suggests Environmental Laws Compel FDA To Ban Oxybenzone, Octinoxate In Sunscreens
Center for Biological Diversity asks FDA to ban using oxybenzone and octinoxate in sunscreens, citing their potential contribution to coral bleaching and coral death as well as potential impact on human health. If the agency does not opt to ban the ingredients, the center asks it to conduct a thorough environmental impact assessment, a measure it suggests is warranted under the National Environmental Policy Act.